Hedrick, L, Epstein, JI. Use of Keratin 903 as an Adjunct in the Diagnosis of Prostate Carcinoma. Am J Surg Pathol. 1989; 13: 389–96.CrossRefGoogle ScholarPubMed

Goldstein, NS, Underhill, J, Roszka, J, Neill, JS. Cytokeratin 34 Beta E-12 Immunoreactivity in Benign Prostatic Acini. Quantitation, Pattern Assessment, and Electron Microscopic Study. Am J Clin Pathol. 1999; 112: 69–74.CrossRefGoogle ScholarPubMed

Wojno, KJ, Epstein, JI. The Utility of Basal Cell-specific Anti-cytokeratin Antibody (34 Beta E12) in the Diagnosis of Prostate Cancer. A Review of 228 Cases. Am J Surg Pathol. 1995; 19: 251–60.CrossRefGoogle Scholar

Shah, RB, Zhou, M, LeBlanc, M, Snyder, M, Rubin, MA. Comparison of the Basal Cell-specific Markers, 34betaE12 and p63, in the Diagnosis of Prostate Cancer. Am J Surg Pathol. 2002; 26: 1161–68.CrossRefGoogle ScholarPubMed

Weinstein, MH, Signoretti, S, Loda, M. Diagnostic Utility of Immunohistochemical Staining for p63, a Sensitive Marker of Prostatic Basal Cells. Mod Pathol. 2002; 15: 1302–08.Google Scholar

Parsons, JK, Gage, WR, Nelson, WG, De Marzo, AM. p63 Protein Expression Is Rare in Prostate Adenocarcinoma: Implications for Cancer Diagnosis and Carcinogenesis. Urology. 2001; 58: 619–24.CrossRefGoogle ScholarPubMed

Sailer, V, Stephan, C, Wernert, N, et al. Comparison of p40 (DeltaNp63) and p63 Expression in Prostate Tissues–Which One Is the Superior Diagnostic Marker for Basal Cells? Histopathology. 2013; 63: 50–56.Google Scholar

Abrahams, NA, Ormsby, AH, Brainard, J. Validation of Cytokeratin 5/6 as an Effective Substitute for Keratin 903 in the Differentiation of Benign from Malignant Glands in Prostate Needle Biopsies. Histopathology. 2002; 41: 35–41.CrossRefGoogle ScholarPubMed

Rubin, MA, Zhou, M, Dhanasekaran, SM, et al. Alpha-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. JAMA. 2002; 287: 1662–70.CrossRefGoogle ScholarPubMed

Zhou, M, Shah, R, Shen, R, Rubin, MA. Basal Cell Cocktail (34betaE12 + p63) Improves the Detection of Prostate Basal Cells. Am J Surg Pathol. 2003; 27: 365–71.Google Scholar

Brimo, F, Epstein, JI. Immunohistochemical Pitfalls in Prostate Pathology. Hum Pathol. 2012; 43: 313–24.Google Scholar

Giannico, GA, Ross, HM, Lotan, T, Epstein, JI. Aberrant Expression of p63 in Adenocarcinoma of the Prostate: A Radical Prostatectomy Study. Am J Surg Pathol. 2013; 37: 1401–06.CrossRefGoogle ScholarPubMed

Zhou, M, Chinnaiyan, AM, Kleer, CG, Lucas, PC, Rubin, MA. Alpha-Methylacyl-CoA Racemase: A Novel Tumor Marker Over-expressed in Several Human Cancers and Their Precursor Lesions. Am J Surg Pathol. 2002; 26: 926–31.Google Scholar

Jiang, Z, Wu, CL, Woda, BA, et al. Alpha-Methylacyl-CoA Racemase: A Multi-institutional Study of a New Prostate Cancer Marker. Histopathology. 2004; 45: 218–25.CrossRefGoogle ScholarPubMed

Magi-Galluzzi, C, Luo, J, Isaacs, WB, Hicks, JL, de Marzo, AM, Epstein, JI. Alpha-Methylacyl-CoA Racemase: A Variably Sensitive Immunohistochemical Marker for the Diagnosis of Small Prostate Cancer Foci on Needle Biopsy. Am J Surg Pathol. 2003; 27: 1128–33.Google Scholar

Zhou, M, Jiang, Z, Epstein, JI. Expression and Diagnostic Utility of Alpha-Methylacyl-CoA-Racemase (P504S) in Foamy Gland and Pseudohyperplastic Prostate Cancer. Am J Surg Pathol. 2003; 27: 772–78.Google Scholar

Kunju, LP, Rubin, MA, Chinnaiyan, AM, Shah, RB. Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations. Am J Clin Pathol. 2003; 120: 737–45.CrossRefGoogle ScholarPubMed

Jiang, Z, Iczkowski, KA, Woda, BA, Tretiakova, M, Yang, XJ. P504S Immunostaining Boosts Diagnostic Resolution of “Suspicious” Foci in Prostatic Needle Biopsy Specimens. Am J Clin Pathol. 2004; 121: 99–107.Google Scholar

Kunju, LP, Chinnaiyan, AM, Shah, RB. Comparison of Monoclonal Antibody (P504S) and Polyclonal Antibody to Alpha Methylacyl-CoA Racemase (AMACR) in the Work-up of Prostate Cancer. Histopathology. 2005; 47: 587–96.Google Scholar

Hameed, O, Sublett, J, Humphrey, PA. Immunohistochemical Stains for p63 and Alpha-Methylacyl-CoA Racemase, versus a Cocktail Comprising both, in the Diagnosis of Prostatic Carcinoma: A Comparison of the Immunohistochemical Staining of 430 Foci in Radical Prostatectomy and Needle Biopsy Tissues. Am J Surg Pathol. 2005; 29: 579–87.Google Scholar

Sanderson, SO, Sebo, TJ, Murphy, LM, Neumann, R, Slezak, J, Cheville, JC. An Analysis of the p63/Alpha-Methylacyl Coenzyme A Racemase Immunohistochemical Cocktail Stain in Prostate Needle Biopsy Specimens and Tissue Microarrays. Am J Clin Pathol. 2004; 121: 220–25.Google Scholar

Jiang, Z, Li, C, Fischer, A, Dresser, K, Woda, BA. Using an AMACR (P504S)/34betaE12/p63 Cocktail for the Detection of Small Focal Prostate Carcinoma in Needle Biopsy Specimens. Am J Clin Pathol. 2005; 123: 231–36.CrossRefGoogle ScholarPubMed

He, H, Magi-Galluzzi, C, Li, J, et al. The Diagnostic Utility of Novel Immunohistochemical Marker ERG in the Workup of Prostate Biopsies with “Atypical Glands Suspicious for Cancer.” Am J Surg Pathol. 2011; 35: 608–14.CrossRefGoogle Scholar

Green, WM, Hicks, JL, De Marzo, A, Illei, PP, Epstein, JI. Immunohistochemical Evaluation of TMPRSS2-ERG Gene Fusion in Adenosis of the Prostate. Hum Pathol. 2013; 44: 1895–901.Google Scholar

Cheng, L, Davidson, DD, Maclennan, GT, et al. Atypical Adenomatous Hyperplasia of Prostate Lacks TMPRSS2-ERG Gene Fusion. Am J Surg Pathol. 2013; 37: 1550–54.CrossRefGoogle ScholarPubMed

Yaskiv, O, Zhang, X, Simmerman, K, et al. The Utility of ERG/p63 Double Immunohistochemical Staining in the Diagnosis of Limited Cancer in Prostate Needle Biopsies. Am J Surg Pathol. 2011; 35: 1062–68.Google Scholar

Minner, S, Gartner, M, Freudenthaler, F, et al. Marked Heterogeneity of ERG Expression in Large Primary Prostate Cancers. Mod Pathol. 2013; 26: 106–16.Google Scholar

Mosquera, JM, Mehra, R, Regan, MM, et al. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States. Clin Cancer Res. 2009; 15: 4706–11.Google Scholar

Shah, RB, Tadros, Y, Brummell, B, Zhou, M. The Diagnostic Use of ERG in Resolving an “Atypical Glands Suspicious for Cancer” Diagnosis in Prostate Biopsies beyond That Provided by Basal Cell and Alpha-Methylacyl-CoA-Racemase Markers. Hum Pathol. 2013; 44: 786–94.CrossRefGoogle Scholar

Pollen, JJ, Dreilinger, A. Immunohistochemical Identification of Prostatic Acid Phosphatase and Prostate Specific Antigen in Female Periurethral Glands. Urology. 1984; 23: 303–04.CrossRefGoogle ScholarPubMed

Nowels, K, Kent, E, Rinsho, K, Oyasu, R. Prostate Specific Antigen and Acid Phosphatase-reactive Cells in Cystitis Cystica and Glandularis. Arch Pathol Lab Med. 1988; 112: 734–37.Google Scholar

Golz, R, Schubert, GE. Prostatic Specific Antigen: Immunoreactivity in Urachal Remnants. J Urol. 1989; 141: 1480–82.Google Scholar

Kamoshida, S, Tsutsumi, Y. Extraprostatic Localization of Prostatic Acid Phosphatase and Prostate-specific Antigen: Distribution in Cloacogenic Glandular Epithelium and Sex-dependent Expression in Human Anal Gland. Hum Pathol. 1990; 21: 1108–11.CrossRefGoogle ScholarPubMed

Sobin, LH, Hjermstad, BM, Sesterhenn, IA, Helwig, EB. Prostatic Acid Phosphatase Activity in Carcinoid Tumors. Cancer. 1986; 58: 136–38.3.0.CO;2-S>CrossRefGoogle ScholarPubMed

Spencer, JR, Brodin, AG, Ignatoff, JM. Clear Cell Adenocarcinoma of the Urethra: Evidence for Origin within Paraurethral Ducts. J Urol. 1990; 143: 122–25.CrossRefGoogle ScholarPubMed

van Krieken, JH. Prostate Marker Immunoreactivity in Salivary Gland Neoplasms. A Rare Pitfall in Immunohistochemistry. Am J Surg Pathol. 1993; 17: 410–14.Google Scholar

Downes, MR, Torlakovic, EE, Aldaoud, N, Zlotta, AR, Evans, AJ, van der Kwast, TH. Diagnostic Utility of Androgen Receptor Expression in Discriminating Poorly Differentiated Urothelial and Prostate Carcinoma. J Clin Pathol. 2013; 66: 779–86.Google Scholar

Chuang, AY, DeMarzo, AM, Veltri, RW, Sharma, RB, Bieberich, CJ, Epstein, JI. Immunohistochemical Differentiation of High-grade Prostate Carcinoma from Urothelial Carcinoma. Am J Surg Pathol. 2007; 31: 1246–55.Google Scholar

Miyamoto, H, Yao, JL, Chaux, A, et al. Expression of Androgen and Oestrogen Receptors and Its Prognostic Significance in Urothelial Neoplasm of the Urinary Bladder. BJU Int. 2012; 109: 1716–26.CrossRefGoogle ScholarPubMed

Varma, M, Morgan, M, Amin, MB, Wozniak, S, Jasani, B. High Molecular Weight Cytokeratin Antibody (clone 34betaE12): A Sensitive Marker for Differentiation of High-grade Invasive Urothelial Carcinoma from Prostate Cancer. Histopathology. 2003; 42: 167–72.Google Scholar

Huang, HY, Shariat, SF, Sun, TT, et al. Persistent Uroplakin Expression in Advanced Urothelial Carcinomas: Implications in Urothelial Tumor Progression and Clinical Outcome. Hum Pathol. 2007; 38: 1703–13.CrossRefGoogle ScholarPubMed

Parker, DC, Folpe, AL, Bell, J, et al. Potential Utility of Uroplakin III, Thrombomodulin, High Molecular Weight Cytokeratin, and Cytokeratin 20 in Noninvasive, Invasive, and Metastatic Urothelial (Transitional Cell) Carcinomas. Am J Surg Pathol. 2003; 27: 1–10.Google Scholar

Ordonez, NG. Thrombomodulin Expression in Transitional Cell Carcinoma. Am J Clin Pathol. 1998; 110: 385–90.Google Scholar

Esheba, GE, Longacre, TA, Atkins, KA, Higgins, JP. Expression of the Urothelial Differentiation Markers GATA3 and Placental S100 (S100P) in Female Genital Tract Transitional Cell Proliferations. Am J Surg Pathol. 2009; 33: 347–53.Google Scholar

Liu, H, Shi, J, Wilkerson, ML, Lin, F. Immunohistochemical Evaluation of GATA3 Expression in Tumors and Normal Tissues: A Useful Immunomarker for Breast and Urothelial Carcinomas. Am J Clin Pathol. 2012; 138: 57–64.Google Scholar

Miettinen, M, McCue, PA, Sarlomo-Rikala, M, et al. GATA3: A Multispecific but Potentially Useful Marker in Surgical Pathology: A Systematic Analysis of 2500 Epithelial and Nonepithelial Tumors. Am J Surg Pathol. 2013.CrossRefGoogle Scholar

Chang, A, Amin, A, Gabrielson, E, et al. Utility of GATA3 Immunohistochemistry in Differentiating Urothelial Carcinoma from Prostate Adenocarcinoma and Squamous Cell Carcinomas of the Uterine Cervix, Anus, and Lung. Am J Surg Pathol. 2012; 36: 1472–76.CrossRefGoogle ScholarPubMed

Genega, EM, Hutchinson, B, Reuter, VE, Gaudin, PB. Immunophenotype of High-grade Prostatic Adenocarcinoma and Urothelial Carcinoma. Mod Pathol. 2000; 13: 1186–91.CrossRefGoogle ScholarPubMed

Mhawech, P, Uchida, T, Pelte, MF. Immunohistochemical Profile of High-grade Urothelial Bladder Carcinoma and Prostate Adenocarcinoma. Hum Pathol. 2002; 33: 1136–40.Google Scholar

Epstein, JI, Kuhajda, FP, Lieberman, PH. Prostate-specific Acid Phosphatase Immunoreactivity in Adenocarcinomas of the Urinary Bladder. Hum Pathol. 1986; 17: 939–42.Google Scholar

Lane, Z, Hansel, DE, Epstein, JI. Immunohistochemical Expression of Prostatic Antigens in Adenocarcinoma and Villous Adenoma of the Urinary Bladder. Am J Surg Pathol. 2008; 32: 1322–26.Google Scholar

Wang, W, Epstein, JI. Small Cell Carcinoma of the Prostate. A Morphologic and Immunohistochemical Study of 95 Cases. Am J Surg Pathol. 2008; 32: 65–71.Google Scholar

Yao, JL, Madeb, R, Bourne, P, et al. Small Cell Carcinoma of the Prostate: An Immunohistochemical Study. Am J Surg Pathol. 2006; 30: 705–12.Google Scholar

Agoff, SN, Lamps, LW, Philip, AT, et al. Thyroid Transcription Factor-1 is Expressed in Extrapulmonary Small Cell Carcinomas But Not in Other Extrapulmonary Neuroendocrine Tumors. Mod Pathol. 2000; 13: 238–42.CrossRefGoogle ScholarPubMed

Ordonez, NG. Value of Thyroid Transcription Factor-1 Immunostaining in Distinguishing Small Cell Lung Carcinomas from Other Small Cell Carcinomas. Am J Surg Pathol. 2000; 24: 1217–23.Google Scholar

Rubenstein, JH, Katin, MJ, Mangano, MM, et al. Small Cell Anaplastic Carcinoma of the Prostate: Seven New Cases, Review of the Literature, and Discussion of a Therapeutic Strategy. Am J Clin Oncol. 1997; 20: 376–80.Google Scholar

Aparicio, AM, Harzstark, AL, Corn, PG, et al. Platinum-based Chemotherapy for Variant Castrate-resistant Prostate Cancer. Clin Cancer Res. 2013; 19: 3621–30.Google Scholar

Han, B, Mehra, R, Lonigro, RJ, et al. Fluorescence in Situ Hybridization Study Shows Association of PTEN Deletion with ERG Rearrangement During Prostate Cancer Progression. Mod Pathol. 2009; 22: 1083–93.CrossRefGoogle ScholarPubMed

Williamson, SR, Zhang, S, Yao, JL, et al. ERG-TMPRSS2 Rearrangement Is Shared by Concurrent Prostatic Adenocarcinoma and Prostatic Small Cell Carcinoma and Absent in Small Cell Carcinoma of the Urinary Bladder: Evidence Supporting Monoclonal Origin. Mod Pathol. 2011; 24: 1120–27.Google Scholar

Schelling, LA, Williamson, SR, Zhang, S, et al. Frequent TMPRSS2-ERG Rearrangement in Prostatic Small Cell Carcinoma Detected by Fluorescence in Situ Hybridization: The Superiority of Fluorescence in Situ Hybridization over ERG Immunohistochemistry. Hum Pathol. 2013.Google Scholar

Bodey, B, Bodey, B Jr, Kaiser, HE. Immunocytochemical Detection of Prostate Specific Antigen Expression in Human Primary and Metastatic Melanomas. Anticancer Res. 1997; 17: 2343–46.Google ScholarPubMed

Fan, CY, Wang, J, Barnes, EL. Expression of Androgen Receptor and Prostatic Specific Markers in Salivary Duct Carcinoma: An Immunohistochemical Analysis of 13 Cases and Review of the Literature. Am J Surg Pathol. 2000; 24: 579–86.Google Scholar

Gurel, B, Ali, TZ, Montgomery, EA, et al. NKX3.1 as a Marker of Prostatic Origin in Metastatic Tumors. Am J Surg Pathol. 2010; 34: 1097–105.Google Scholar

Miettinen, M, Wang, ZF, Paetau, A, et al. ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma. Am J Surg Pathol. 2011; 35: 432–41.Google Scholar

Sheridan, T, Herawi, M, Epstein, JI, Illei, PB. The role of P501S and PSA in the Diagnosis of Metastatic Adenocarcinoma of the Prostate. Am J Surg Pathol. 2007; 31: 1351–55.Google Scholar

Tazawa, K, Kurihara, Y, Kamoshida, S, Tsukada, K, Tsutsumi, Y. Localization of Prostate-specific Antigen-like Immunoreactivity in Human Salivary Gland and Salivary Gland Tumors. Pathol Int. 1999; 49: 500–05.Google Scholar

Yin, M, Dhir, R, Parwani, AV. Diagnostic Utility of p501s (Prostein) in Comparison to Prostate Specific Antigen (PSA) for the Detection of Metastatic Prostatic Adenocarcinoma. Diagn Pathol. 2007; 2: 41.Google Scholar

Paterson, RF, Gleave, ME, Jones, EC, Zubovits, JT, Goldenberg, SL, Sullivan, LD. Immunohistochemical Analysis of Radical Prostatectomy Specimens after 8 Months of Neoadjuvant Hormonal Therapy. Mol Urol. 1999; 3: 277–86.Google ScholarPubMed

Oppenheimer, JR, Kahane, H, Epstein, JI. Granulomatous Prostatitis on Needle Biopsy. Arch Pathol Lab Med. 1997; 121: 724–29.Google ScholarPubMed

Chuang, AY, Epstein, JI. Xanthoma of the Prostate: A Mimicker of High-grade Prostate Adenocarcinoma. Am J Surg Pathol. 2007; 31: 1225–30.Google Scholar

Cheville, JC, Dundore, PA, Nascimento, AG, et al. Leiomyosarcoma of the Prostate. Report of 23 Cases. Cancer. 1995; 76: 1422–27.Google Scholar

Westfall, DE, Folpe, AL, Paner, GP, et al. Utility of a Comprehensive Immunohistochemical Panel in the Differential Diagnosis of Spindle Cell Lesions of the Urinary Bladder. Am J Surg Pathol. 2009; 33: 99–105.Google Scholar

Jo, VY, Fletcher, CD. p63 Immunohistochemical Staining is Limited in Soft Tissue Tumors. Am J Clin Pathol. 2011; 136: 762–66.Google Scholar

Hansel, DE, Herawi, M, Montgomery, E, Epstein, JI. Spindle Cell Lesions of the Adult Prostate. Mod Pathol. 2007; 20: 148–58.Google Scholar

Gaudin, PB, Rosai, J, Epstein, JI. Sarcomas and Related Proliferative Lesions of Specialized Prostatic Stroma: A Clinicopathologic Study of 22 Cases. Am J Surg Pathol. 1998; 22: 148–62.Google Scholar

Herawi, M, Epstein, JI. Specialized Stromal Tumors of the Prostate: A Clinicopathologic Study of 50 Cases. Am J Surg Pathol. 2006; 30: 694–704.CrossRefGoogle ScholarPubMed

Bostwick, DG, Hossain, D, Qian, J, et al. Phyllodes Tumor of the Prostate: Long-term Followup Study of 23 Cases. J Urol. 2004; 172: 894–99.CrossRefGoogle ScholarPubMed

Dundore, PA, Cheville, JC, Nascimento, AG, Farrow, GM, Bostwick, DG. Carcinosarcoma of the Prostate. Report of 21 Cases. Cancer. 1995; 76: 1035–42.3.0.CO;2-8>CrossRefGoogle ScholarPubMed

Osunkoya, AO, Netto, GJ, Epstein, JI. Colorectal Adenocarcinoma Involving the Prostate: Report of 9 Cases. Hum Pathol. 2007 38: 1836–41.Google Scholar

Owens, CL, Epstein, JI, Netto, GJ. Distinguishing Prostatic from Colorectal Adenocarcinoma on Biopsy Samples: The Role of Morphology and Immunohistochemistry. Arch Pathol Lab Med. 2007; 131: 599–603.Google Scholar

Jaggi, M, Johansson, SL, Baker, JJ, Smith, LM, Galich, A, Balaji, KC. Aberrant Expression of E-cadherin and Beta-Catenin in Human Prostate Cancer. Urol Oncol. 2005; 23: 402–06.Google Scholar

Lazari, P, Poulias, H, Gakiopoulou, H, Thomopoulou, GH, Barbatis, C, Lazaris, AC. Differential Immunohistochemical Expression of CD44s, E-cadherin and Beta-Catenin among Hyperplastic and Neoplastic Lesions of the Prostate Gland. Urol Int. 2013; 90: 109–16.Google Scholar

Whitaker, HC, Girling, J, Warren, AY, Leung, H, Mills, IG, Neal, DE. Alterations in Beta-Catenin Expression and Localization in Prostate Cancer. Prostate. 2008; 68: 1196–205.Google Scholar

Aslan, G, Irer, B, Tuna, B, Yorukoglu, K, Saatcioglu, F, Celebi, I. Analysis of NKX3.1 Expression in Prostate Cancer Tissues and Correlation with Clinicopathologic Features. Pathol Res Pract. 2006; 202: 93–98.CrossRefGoogle ScholarPubMed

Bauer, JJ, Sesterhenn, IA, Mostofi, KF, McLeod, DG, Srivastava, S, Moul, JW. P53 Nuclear Protein Expression is an Independent Prognostic Marker in Clinically Localized Prostate Cancer Patients Undergoing Radical Prostatectomy. Clin Cancer Res. 1995; 1: 1295–300.Google Scholar

Bethel, CR, Faith, D, Li, X, et al. Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion. Cancer Res. 2006; 66: 10683–90.Google Scholar

Brewster, SF, Oxley, JD, Trivella, M, Abbott, CD, Gillatt, DA. Preoperative p53, bcl-2, CD44 and E-cadherin Immunohistochemistry as Predictors of Biochemical Relapse after Radical Prostatectomy. J Urol. 1999; 161: 1238–43.Google Scholar

Cheng, L, Pisansky, TM, Sebo, TJ, et al. Cell Proliferation in Prostate Cancer Patients with Lymph Node Metastasis: A Marker for Progression. Clin Cancer Res. 1999; 5: 2820–23.Google Scholar

Gurel, B, Iwata, T, Koh, CM, et al. Nuclear MYC Protein Overexpression Is an Early Alteration in Human Prostate Carcinogenesis. Mod Pathol. 2008; 21: 1156–67.Google Scholar

Gurel, B, Iwata, T, Koh, CM, Yegnasubramanian, S, Nelson, WG, De Marzo, AM. Molecular Alterations in Prostate Cancer as Diagnostic, Prognostic, and Therapeutic Targets. Adv Anat Pathol. 2008; 15: 319–31.Google Scholar

Kuczyk, MA, Serth, J, Bokemeyer, C, et al. The Prognostic Value of p53 for Long-term and Recurrence-free Survival Following Radical Prostatectomy. Eur J Cancer. 1998; 34: 679–86.CrossRefGoogle ScholarPubMed

Lotan, TL, Gurel, B, Sutcliffe, S, et al. PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clin Cancer Res. 2011; 17: 6563–73.Google Scholar

Moul, JW, Bettencourt, MC, Sesterhenn, IA, et al. Protein Expression of p53, bcl-2, and KI-67 (MIB-1) as Prognostic Biomarkers in Patients with Surgically Treated, Clinically Localized Prostate Cancer. Surgery. 1996; 120: 159–66. Discussion 166–67.Google Scholar

Sarker, D, Reid, AH, Yap, TA, de Bono, JS. Targeting the PI3 K/AKT Pathway for the Treatment of Prostate Cancer. Clin Cancer Res. 2009; 15: 4799–805.Google Scholar

Stapleton, AM, Zbell, P, Kattan, MW, et al. Assessment of the Biologic Markers p53, Ki-67, and Apoptotic Index as Predictive Indicators of Prostate Carcinoma Recurrence after Surgery. Cancer. 1998; 82: 168–75.Google Scholar

Wang, HL, Lu, DW, Yerian, LM, et al. Immunohistochemical Distinction between Primary Adenocarcinoma of the Bladder and Secondary Colorectal Adenocarcinoma. Am J Surg Pathol. 2001; 25: 1380–87.Google Scholar

Mhawech-Fauceglia, P, Zhang, S, Terracciano, L, et al. Prostate-specific Membrane Antigen (PSMA) Protein Expression in Normal and Neoplastic Tissues and Its Sensitivity and Specificity in Prostate Adenocarcinoma: An Immunohistochemical Study Using Multiple Tumour Tissue Microarray Technique. Histopathology. 2007; 50: 472–83.Google Scholar

Herawi, M, De Marzo, AM, Kristiansen, G, Epstein, JI. Expression of CDX2 in Benign Tissue and Adenocarcinoma of the Prostate. Hum Pathol. 2007; 38: 72–78.Google Scholar

Lopez-Beltran, A, Cheng, L, Prieto, R, lanca, A, Montironi, R. Lymphoepithelioma-like Carcinoma of the Prostate. Hum Pathol. 2009 Jul; 40(7): 982–87.Google Scholar

Suh, N, Yang, XJ, Tretiakova, MS, Humphrey, PA, Wang, HL. Value of CDX2, Villin, and Alpha-Methylacyl Coenzyme A Racemase Immunostains in the Distinction between Primary Adenocarcinoma of the Bladder and Secondary Colorectal Adenocarcinoma. Mod Pathol. 2005; 18: 1217–22.Google Scholar